Trop2-targeted therapy in breast cancer.

Biomark Res · 2024 · PMC11321197 · PMID 39135109

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

4.9 months; HR = 0.63; 95%CI, 0.52–0.76; p < 0.0001), and OS also showed a trend towards benefit (HR = 0.84) [ 87 ].

also in 53,322 other papers

did not reach statistical significanceno p-value reported

The results showed that, compared to the docetaxel group, patients in SG group had a slightly longer OS, but it did not reach statistical significance (mOS 11.1 vs. 9.8 months, HR 0.84).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.